Predictors of infarct-related artery patency following combined lytic therapy in patients with ST-segment elevation myocardial infarction treated with immediate percutaneous coronary intervention

Kardiologia Polska

Volumn 69, Issue 5, 2011, Pages 452-457

  Rakowski, Tomasz ^a   Dziewierz, Artur ^a   Siudak, Zbigniew ^a   Mielecki, Waldemar ^a   Bierca, Katarzyna ^a   Legutko, Jacek ^a   Dubiel, Jacek S ^a   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiography; Infarct related artery; Reperfusion; ST elevation myocardial infarction; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DEVICE THERAPY; FEMALE; FIBRINOLYTIC THERAPY; GUIDE WIRE; HUMAN; INFARCT RELATED ARTERY PATENCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR PATENCY;

EID: 79957666405     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stone GW, Cox D, Garcia E et al. Normal flow (TIMI 3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Analysis from the Primary Angioplasty in Myocardial Infarction Trials. Circulation, 2001; 104: 636-641.
2. Brodie BR, Stuckey TD, Hansen C et al. Benefit of coronary reperfusion before intervention on outcome after primary angioplasty for acute myocardial infarction. Am J Cardiol, 2000; 85: 13-18. (Pubitemid 30045537)
3. Dudek D, Rakowski T, El Massri N et al. Patency of infarct-related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome. Int J Cardiol, 2008; 124: 326-331. (Pubitemid 351305379)
4. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med, 1985; 312: 932-936.
5. Wang JC, Normand SL, Mauri L et al. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation, 2004; 110: 278-284. (Pubitemid 38960797)
6. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J, 2008; 29: 2909-2945.
7. Kushner FG, Hand M, Smith SC Jr et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutane ous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2009; 120: 2271-2306.
8. Dudek D, Legutko J, Siudak Z et al. Invasive treatment strategies in patients with myocardial infarction in Poland. Kardiol Pol, 2010; 68: 618-624.
9. Ga̧sior M, Wilczek K, Lekston A et al. Influence of baseline infarct-related artery flow on outcome in patients with acute myocardial infarction coronary angioplasty. Cardiol J, 2003; 10: 467-474. (Pubitemid 37139118)
10. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet, 2006; 367: 579-588. (Pubitemid 43247573)
11. De Luca G, Gibson CM, Bellandi F et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) co-operation. An individual patient's data meta-analysis. Heart, 2008; 94: 1548-1558.
12. Rakowski T, Siudak Z, Dziewierz A et al. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces one-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J, 2009; 158: 569-575.
13. Herrmann HC, Lu J, Brodie BR et al.; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. J Am Coll Cardiol Cardiovasc Interv, 2009; 2: 917-924.
14. Ellis SG, Tendera M, de Belder MA et al.; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med, 2008; 358: 2205-2217. (Pubitemid 351724450)
15. Gomez MA, Karagounis LA, Allen A et al. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 Investigators. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. Am J Cardiol, 1993; 72: 373-378.
16. Lundergan CF, Reiner JS, McCarthy WF et al. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol, 1998; 32: 641-647. (Pubitemid 28435247)
17. Barbash GI, Reiner J, White HD et al. Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the 'smoker's paradox' from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol, 1995; 26: 1222-1229.
18. Bode C, Smalling RW, Berg G et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation, 1996; 94: 891-898.
19. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest, 2002; 122: 1322-1332.
20. Gibson CM, Murphy S, Menown IB et al. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol, 1999; 34: 1403-1412. (Pubitemid 29528650)
21. Moliterno DJ, Lange RA, Meidell RS et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation, 1993; 88: 935-940. (Pubitemid 23264008)
22. Jang IK, Gold HK, Ziskind AA et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation, 1989; 79: 920-928.
23. Antman EM, Van De Werf F. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation, 2004; 109: 2480-2486. (Pubitemid 38720543)
24. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction ASSENT-4 PCI: randomized trial. Lancet, 2006; 367: 569-578.
25. Collet JP, Montalescot G, Le May M et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analysis approach according to the type of strategy. J Am Coll Cardiol, 2006; 48: 1326-1335. (Pubitemid 44436802)